Recurrent Glioblastoma, IDH-Wildtype
Oncology·MeSH: Glioblastoma
Prevalence
3.2 / 100K
Incidence
3.2 / 100K/yr
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 1(1)
Frequently asked questions
How many drugs are in development for Recurrent Glioblastoma, IDH-Wildtype?
BioSniper tracks 1 drug in development for Recurrent Glioblastoma, IDH-Wildtype across 1 company.
How many clinical trials target Recurrent Glioblastoma, IDH-Wildtype?
There are 2 clinical trials targeting Recurrent Glioblastoma, IDH-Wildtype tracked by BioSniper.
What is the prevalence of Recurrent Glioblastoma, IDH-Wildtype?
The estimated prevalence of Recurrent Glioblastoma, IDH-Wildtype is approximately 3.2 per 100,000 population.
Deep-dive into Recurrent Glioblastoma, IDH-Wildtype
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis